[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599977":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":37,"centralContacts":44,"locations":50,"responsibleParty":66,"collaborators":27,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":27,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":27,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":27,"overallStatus":52,"whyStopped":27,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Washington University School of Medicine","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"GLP-1 RA","ACTIVE_COMPARATOR","Participants in this group will receive semaglutide therapy along with diet behavior counseling for 52 weeks",[13,14],"Drug: Semaglutide","Behavioral: Therapy Cessation",{"label":16,"type":17,"description":18,"interventionNames":19},"GLP-1 RA + Exercise","EXPERIMENTAL","Participants in this group will receive semaglutide therapy along with diet behavior counseling and exercise training for 52 weeks.",[20,13,14],"Behavioral: Exercise training",[22,28,33],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"BEHAVIORAL","Exercise training","Participants will perform supervised exercise training sessions 3 days per week and unsupervised at-home sessions 2-3 days per week.",[16],null,{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":27},"DRUG","Semaglutide","semaglutide 2.4 mg subcutaneous per week or max tolerated dose and diet behavior counseling",[9,16],{"type":23,"name":34,"description":35,"armGroupLabels":36,"otherNames":27},"Therapy Cessation","After 1 year of treatment, participants will stop taking GLP-1 medications (and exercise, if applicable)",[9,16],[38,41],{"name":39,"affiliation":5,"role":40},"Joseph W Beals, PhD","STUDY_DIRECTOR",{"name":42,"affiliation":5,"role":43},"Samuel Klein, MD","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":27,"email":49},"Coordinator","CONTACT","314-273-1879","NutritionResearch@wustl.edu",[51],{"facility":5,"status":52,"city":53,"state":54,"zip":55,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":64},"RECRUITING","St Louis","Missouri","63110","United States","US",{"type":59,"coordinates":60},"Point",[61,62],-90.19789,38.62727,{"lat":62,"lon":61},[65],{"name":46,"role":47,"phone":48,"phoneExt":27,"email":27},{"type":67,"investigatorFullName":27,"investigatorTitle":27,"investigatorAffiliation":27,"oldNameTitle":27,"oldOrganization":27},"SPONSOR","100599977","glucagon-like-peptide-1-glp-1-receptor-agonist-therapy-and-exercise-training-in-people-with-obesity-100599977",false,"NCT07091500","Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Therapy and Exercise Training in People With Obesity","Effect of GLP-1 Receptor Agonist Therapy With and Without Exercise Training on Muscle Mass and Physical Function in People With Obesity","Inclusion Criteria:\n\n* i) obesity (Body Mass Index ≥ 30 kg\u002Fm2)\n* ii) decreased physical function (Modified Physical Performance Test score 17 to 31)\n* iii) approval of their primary physician to participate in this study.\n\nExclusion Criteria:\n\n* i) unstable weight (\\>4% change during the last 2 months before entering the study)\n* ii) ≥150 min per week of structured exercise (e.g., jogging, activities that cause heavy breathing and sweating)\n* iii) diabetes\n* iv) significant cardiopulmonary disease (heart failure, angina, uncontrolled hypertension, chronic obstructive pulmonary disease) or other organ dysfunction (e.g., renal insufficiency \\[eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\\])\n* v) therapy with a GLP-1 or other weight loss medications\n* vi) clinically significant gastric emptying abnormality or chronically take drugs that directly affect gastrointestinal motility\n* vii) history of chronic or acute pancreatitis\n* viii) thyroid-stimulating hormone (TSH) \\>1.5X the upper limit of normal (patients receiving treatment for hypothyroidism may be included provided their thyroid hormone replacement dose has been stable for at least 3 months)\n* ix) history of significantly active or unstable Major Depressive Disorder or other severe psychiatric disorder (e.g. schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within the last 2 months that would interfere with study participation\n* x) acute or chronic hepatitis, or other liver disease other than Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD)\n* xi) family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2\n* xii) history of active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years\n* xiii) tobacco use, excessive alcohol intake (≥3 drinks\u002Fday for men and ≥2 drinks\u002Fday for women) or active substance abuse with illegal drugs by self-report, or regular marijuana use within 3 months of enrollment and unwilling to abstain from marijuana during the trial\n* xiv) Use of medications that are known to affect the study outcome measures or increase the risk of study procedures and that cannot be temporarily discontinued for this study\n* xv) have had bariatric surgery or plan to have endoscopic or bariatric surgery therapy for obesity\n* xvi) anemia (Hgb \\\u003C10 g\u002FdL)\n* xvii) Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)\n* xii) history of seizure disorder\n* xix) Female who is pregnant, breast-feeding or intends to become pregnant\n* xx) allergy or hypersensitivity to GLP-1 RA medications\n* xxi) unable to grant voluntary informed consent\n* xxii) unable or unwilling to follow the study protocol or who, for any reason, the research team considers the participant is not an appropriate candidate for the study","ALL","50 Years","75 Years",{"count":79,"type":80},40,"ESTIMATED","INTERVENTIONAL",[83],"NA","The use of glucagon-like peptide receptor agonists (GLP-1 RAs) may have clinically important effects on skeletal muscle mass (SMM), and physical function. The effects of exercise training in conjunction with GLP-1 RA therapy on these outcomes has not been studied. Additionally, most people treated with GLP-1-based weight loss medications stop taking these medications within 1 year of initiating treatment. This is an important clinical concern because weight regain can occur after weight loss pharmacotherapy is stopped and the impact of stopping GLP-1 RA therapy on physical and metabolic function has not been studied.\n\nIn this study, the investigators will conduct a 2-year randomized clinical trial to evaluate body composition, muscle, physical and metabolic function, muscle strength and appetite control and reward signaling in the brain in response to 1-year of GLP-1 RA therapy, with or without exercise training, and subsequent treatment cessation on muscle and appetite-related outcomes assessed 1-year after stopping treatment.",[86,87,88],"Obesity","Skeletal Muscle","Brain Connectivity","2026-07-08",{"date":91,"type":92},"2026-07-10","ACTUAL",{"date":94,"type":92},"2025-08-11",{"date":96,"type":80},"2029-08-01",{"name":5,"class":6},1]